{"id":64710,"date":"2026-05-08T14:18:06","date_gmt":"2026-05-08T06:18:06","guid":{"rendered":"https:\/\/flcube.com\/?p=64710"},"modified":"2026-05-08T14:18:07","modified_gmt":"2026-05-08T06:18:07","slug":"guangdong-zhongsheng-pharma-reports-positive-phase-iib-results-for-first-in-class-zsp1601-in-metabolic-dysfunction-associated-steatohepatitis-with-fibrosis-reversal-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64710","title":{"rendered":"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential"},"content":{"rendered":"\n<p><strong>Guangdong Zhongsheng Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002317:SHE\">SHE: 002317<\/a>) announced <strong>positive top-line results<\/strong> from its <strong>Phase IIb clinical trial<\/strong> of <strong>ZSP1601<\/strong>, a <strong>First-in-Class Class 1 innovative drug<\/strong> for <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong>. Both dose groups demonstrated <strong>statistically significant superiority over placebo<\/strong> in primary efficacy endpoints and showed <strong>potential to reverse liver fibrosis<\/strong>, positioning the candidate for advancement to <strong>Phase III development<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-overview\">Clinical Development Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial Phase<\/th><th>Key Findings<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase Ib\/IIa<\/strong><\/td><td>Significant reductions in serum transaminases and liver fat content after 28 days; decreasing trends in non-invasive fibrosis biomarkers<\/td><td>Established proof-of-concept and dose selection<\/td><\/tr><tr><td><strong>Phase IIb<\/strong><\/td><td>Primary endpoint response rates significantly superior to placebo in both dose groups; demonstrated fibrosis reversal potential<\/td><td>Pivotal data supporting Phase III advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation-highlights\">Drug Profile &amp; Innovation Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-molecular-characteristics\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification<\/strong>: First-in-Class Class 1 innovative drug with <strong>globally independent intellectual property rights<\/strong><\/li>\n\n\n\n<li><strong>Target Indication<\/strong>: Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong>: Novel pathway targeting liver inflammation, hydropic degeneration, necrosis, and fibrosis simultaneously<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Advancing to Phase III following successful Phase IIb completion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h3>\n\n\n\n<p>Multiple MASH animal models demonstrated that ZSP1601:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Improves <strong>liver inflammation<\/strong> and cellular damage<\/li>\n\n\n\n<li>Reduces <strong>hydropic degeneration<\/strong> and <strong>necrosis<\/strong><\/li>\n\n\n\n<li>Shows <strong>notable fibrosis-improving effects<\/strong>, suggesting disease-modifying potential<\/li>\n\n\n\n<li>Positions as <strong>core foundational drug<\/strong> for future MASH combination therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-ib-iia-results\">Phase Ib\/IIa Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dosing Regimens<\/strong>: 50 mg BID and 100 mg BID for 28 days<\/li>\n\n\n\n<li><strong>Primary Outcomes<\/strong>: Significant reductions in <strong>serum transaminase levels<\/strong> and <strong>liver fat content<\/strong> versus placebo<\/li>\n\n\n\n<li><strong>Secondary Signals<\/strong>: Decreasing trends in <strong>non-invasive fibrosis indicators<\/strong> and established MASH biomarkers<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Well-tolerated with no dose-limiting toxicities reported<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-iib-top-line-data\">Phase IIb Top-Line Data<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint<\/strong>: Response rates in both ZSP1601 dose groups <strong>significantly superior<\/strong> to placebo<\/li>\n\n\n\n<li><strong>Key Differentiator<\/strong>: Demonstrated <strong>potential to reverse liver fibrosis<\/strong>, addressing critical unmet need in MASH treatment<\/li>\n\n\n\n<li><strong>Statistical Significance<\/strong>: p-values and effect sizes to be disclosed in full data presentation at upcoming medical conference<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mash-market-dynamics\">MASH Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Prevalence<\/strong>: Over <strong>100 million MASH patients worldwide<\/strong>, with <strong>30\u201340 million in China alone<\/strong><\/li>\n\n\n\n<li><strong>Market Value<\/strong>: Global MASH therapeutics market projected to reach <strong>$12 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: No approved pharmacotherapies specifically for MASH with fibrosis reversal capability<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-positioning\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class Status<\/strong>: Novel mechanism distinct from FXR agonists, ACC inhibitors, and other approaches in development<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Designed as <strong>foundational therapy<\/strong> for future combination regimens<\/li>\n\n\n\n<li><strong>Intellectual Property<\/strong>: Global patent protection provides extended market exclusivity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-and-commercial-strategy\">Regulatory and Commercial Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Initiation<\/strong>: Expected Q4 2026 following final Phase IIb data analysis<\/li>\n\n\n\n<li><strong>Regulatory Pathways<\/strong>: Parallel development plans for <strong>NMPA (China)<\/strong> and <strong>FDA (US)<\/strong> submissions<\/li>\n\n\n\n<li><strong>Fast Track Consideration<\/strong>: Potential for breakthrough therapy designation based on fibrosis reversal data<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-projections\">Commercial Projections<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Sales Estimate<\/strong>: Analysts project <strong>\u00a51.5\u20132.5 billion<\/strong> ($210\u2013350 million) annual revenue at peak penetration<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Premium pricing justified by first-in-class status and fibrosis reversal capability<\/li>\n\n\n\n<li><strong>Reimbursement Target<\/strong>: Inclusion in <strong>National Reimbursement Drug List (NRDL)<\/strong> negotiations anticipated for 2028<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Performance<\/strong>: SHE: 002317 closed at \u00a518.75 on May 7, 2026; trading volume expected to increase significantly<\/li>\n\n\n\n<li><strong>Pipeline Valuation<\/strong>: ZSP1601 represents the company&#8217;s most valuable asset; successful Phase III could triple enterprise value<\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Major pharmaceutical companies likely monitoring development progress for licensing opportunities<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory timelines, and commercial projections for ZSP1601. Actual outcomes may differ due to regulatory review processes, competitive developments, and clinical trial execution risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u6cbb\u7597MASH\u4e00\u7c7b\u521b\u65b0\u836fZSP1601\u7247IIb\u671f\u4e34\u5e8a\u8bd5\u9a8c\u521d\u6b65\u7ed3\u679c\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u6cbb\u7597MASH\u4e00\u7c7b\u521b\u65b0\u836fZSP1601\u7247IIb\u671f\u4e34\u5e8a\u8bd5\u9a8c\u521d\u6b65\u7ed3\u679c\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-7f712fe4-878d-4043-acc5-1e67c182ad3f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u6cbb\u7597MASH\u4e00\u7c7b\u521b\u65b0\u836fZSP1601\u7247IIb\u671f\u4e34\u5e8a\u8bd5\u9a8c\u521d\u6b65\u7ed3\u679c\u7684\u516c\u544a.pdf\">\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u6cbb\u7597MASH\u4e00\u7c7b\u521b\u65b0\u836fZSP1601\u7247IIb\u671f\u4e34\u5e8a\u8bd5\u9a8c\u521d\u6b65\u7ed3\u679c\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u6cbb\u7597MASH\u4e00\u7c7b\u521b\u65b0\u836fZSP1601\u7247IIb\u671f\u4e34\u5e8a\u8bd5\u9a8c\u521d\u6b65\u7ed3\u679c\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7f712fe4-878d-4043-acc5-1e67c182ad3f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,76,1197,399],"class_list":["post-64710","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nash","tag-she-002317","tag-zhongsheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb clinical trial of ZSP1601, a First-in-Class Class 1 innovative drug for metabolic dysfunction-associated steatohepatitis (MASH). Both dose groups demonstrated statistically significant superiority over placebo in primary efficacy endpoints and showed potential to reverse liver fibrosis, positioning the candidate for advancement to Phase III development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64710\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential\" \/>\n<meta property=\"og:description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb clinical trial of ZSP1601, a First-in-Class Class 1 innovative drug for metabolic dysfunction-associated steatohepatitis (MASH). Both dose groups demonstrated statistically significant superiority over placebo in primary efficacy endpoints and showed potential to reverse liver fibrosis, positioning the candidate for advancement to Phase III development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64710\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T06:18:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64710#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64710\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential\",\"datePublished\":\"2026-05-08T06:18:06+00:00\",\"dateModified\":\"2026-05-08T06:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64710\"},\"wordCount\":567,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"NASH\",\"SHE: 002317\",\"Zhongsheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64710#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64710\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64710\",\"name\":\"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T06:18:06+00:00\",\"dateModified\":\"2026-05-08T06:18:07+00:00\",\"description\":\"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb clinical trial of ZSP1601, a First-in-Class Class 1 innovative drug for metabolic dysfunction-associated steatohepatitis (MASH). Both dose groups demonstrated statistically significant superiority over placebo in primary efficacy endpoints and showed potential to reverse liver fibrosis, positioning the candidate for advancement to Phase III development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64710#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64710\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64710#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb clinical trial of ZSP1601, a First-in-Class Class 1 innovative drug for metabolic dysfunction-associated steatohepatitis (MASH). Both dose groups demonstrated statistically significant superiority over placebo in primary efficacy endpoints and showed potential to reverse liver fibrosis, positioning the candidate for advancement to Phase III development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64710","og_locale":"en_US","og_type":"article","og_title":"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential","og_description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb clinical trial of ZSP1601, a First-in-Class Class 1 innovative drug for metabolic dysfunction-associated steatohepatitis (MASH). Both dose groups demonstrated statistically significant superiority over placebo in primary efficacy endpoints and showed potential to reverse liver fibrosis, positioning the candidate for advancement to Phase III development.","og_url":"https:\/\/flcube.com\/?p=64710","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T06:18:06+00:00","article_modified_time":"2026-05-08T06:18:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64710#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64710"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential","datePublished":"2026-05-08T06:18:06+00:00","dateModified":"2026-05-08T06:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64710"},"wordCount":567,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","NASH","SHE: 002317","Zhongsheng Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64710#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64710","url":"https:\/\/flcube.com\/?p=64710","name":"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T06:18:06+00:00","dateModified":"2026-05-08T06:18:07+00:00","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb clinical trial of ZSP1601, a First-in-Class Class 1 innovative drug for metabolic dysfunction-associated steatohepatitis (MASH). Both dose groups demonstrated statistically significant superiority over placebo in primary efficacy endpoints and showed potential to reverse liver fibrosis, positioning the candidate for advancement to Phase III development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64710#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64710"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64710#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64710"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64710\/revisions"}],"predecessor-version":[{"id":64713,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64710\/revisions\/64713"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}